Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

ACCP is a non-profit association providing accredited Continuing Education, publications and career-enhancing opportunities to clinical pharmacology healthcare professionals. We sell different ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...

Basic science researchers at the Johns Hopkins University School of Medicine are advancing heart health research by finding ...

published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists". Obesity is a multifaceted disease with increasing prevalence and profound ...